论文信息 - Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model - 字舞流文

Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

S. Orsulic | M. Raponi | T. Harding | L. Robillard | R. Kristeleit | A. Simmons | M. Nguyen | A. Loehr | K. Lin